ONCT 534
Alternative Names: GTX 534; GTx-534; ONCT-534Latest Information Update: 24 Oct 2024
Price :
$50 *
At a glance
- Originator University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.
- Class Antiandrogens; Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists; Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 22 Oct 2024 Efficacy and adverse events from phase I/II trial in Prostate cancer (Second-line therapy or greater, Metastatic disease, Hormone refractory) released by Oncternal Therapeutics (PO)
- 25 Sep 2024 Oncternal Therapeutics terminates phase-I/II clinical trials in Prostate cancer (Second-line therapy or greater, Metastatic disease, Hormone refractory) in USA and United Kingdom (PO) due to interim results of phase I (NCT05917470)
- 12 Sep 2024 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)